Adipocyte-derived exosomal miR-21 drives erythropoietin resistance in aged bone marrow by suppressing EPOR expression
Hypothesis
Aged bone marrow adipocytes release exosomes enriched in miR-21 that directly inhibit erythropoietin receptor (EPOR) translation in early erythroblasts, producing the observed STAT5 phosphorylation defect and contributing to age‑related anemia.
Mechanistic rationale
- Adipocyte expansion in the marrow niche correlates with increased extracellular vesicle secretion (4).
- miR-21 is known to target the 3′‑UTR of EPOR mRNA, reducing receptor density without altering gene transcription (hypothetical but supported by analogous miR‑mediated repression in other hematopoietic contexts).
- Lower EPOR levels diminish ligand‑induced JAK2 activation, leading to reduced STAT5‑pY694 specifically in CD71⁺CD235a⁻ progenitors, matching the phosphorylation deficit reported in older marrow (1).
- Because the defect resides upstream of JAK2, exogenous EPO cannot overcome the block, explaining poor therapeutic response.
Testable predictions
- Exosome isolation – Flow‑sorted adipocytes from 20‑month‑old mice will yield exosomes with miR‑21 levels ≥3‑fold higher than those from 3‑month‑old controls (qPCR).
- Functional transfer – Incubating CD71⁺CD235a⁻ erythroblasts from young mice with aged‑adipocyte exosomes will decrease EPOR surface staining by ~40 % and cut STAT5‑pY694 after EPO stimulation by half.
- Loss‑of‑function – Treating aged mice with the exosome secretion inhibitor GW4869 (intraperitoneal, 5 mg/kg daily for 2 weeks) will reduce marrow miR‑21‑exosome content, increase EPOR density on early erythroblasts, and restore STAT5 phosphorylation to youthful levels without elevating serum M‑CSF.
- Rescue specificity – Adding a miR‑21 antagomir to aged‑adipocyte exosomes before transfer will abolish the inhibitory effect on EPOR, confirming miR‑21 as the active cargo.
- Clinical correlate – In elderly patients with anemia, plasma exosomal miR-21 concentration will inversely correlate with baseline EPOR‑dependent STAT5 phosphorylation in circulating CD71⁺CD235a⁻ cells and predict poor response to epoetin therapy.
Potential confounders and controls
- Verify that GW4869 does not directly affect osteoclast precursors (measure TRAP‑positive cells) to exclude off‑target bone effects.
- Use adipocyte‑specific Cre‑driven Dicer knockout mice to genetically block miRNA loading into exosomes as an orthogonal approach.
- Control for inflammation by measuring IL-6 and IL-1β; the hypothesis predicts that miR‑21‑exosome effects are independent of cytokine levels.
Implications
If validated, targeting adipocyte‑derived exosomal miR-21 would uncouple erythropoietic rescue from niche‑wide inflammation, offering a strategy that avoids the M‑CSF‑driven osteoclast expansion seen with high‑dose EPO monotherapy (3).